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Summary
Objectives—Routine monitoring after the initial treatment of differentiated thyroid cancer 
(DTC) includes periodic cervical ultrasonography (US) and measurement of serum thyroglobulin 
(Tg) during thyrotrophin (TSH) suppression and after recombinant human TSH (rhTSH) 
stimulation. The aim of our study was to evaluate the utility of repeated rhTSH-stimulated Tg 
measurements in patients with DTC who have had no evidence of disease at their initial rhTSH 
stimulation test performed 1 year after the treatment.
Material and methods—A retrospective chart review of 278 patients with DTC who had 
repeated rhTSH stimulation testing after an initial undetectable rhTSH-stimulated serum Tg level.
Results—The number of rhTSH stimulation tests performed on individual patients during the 
follow-up period (3–12 years, mean 6·3) varied from two to seven. Biochemical and/or cytological 
evidence of potential persistent/recurrent disease based on detectable second or third rhTSH-
stimulated Tg values and US findings was observed in 11 (4%) patients. Subsequent follow-up 
data revealed that in five cases, the results of the second stimulation were false positive, in one 
case – false negative. Combined with the negative neck US, the negative predictive value for 
disease-free survival was 98% after the first undetectable rhTSH-stimulated Tg and 100% after the 
second one.
Conclusions—In patients with DTC, the intensity of follow-up should be adjusted to new risk 
estimates evolving with time. The first rhTSH-stimulated Tg is an excellent predictor for 
remission, independent of clinical stage at presentation. Second negative rhTSH-Tg stimulation is 
additionally reassuring and can guide less aggressive follow-up by the measurement of 
nonstimulated Tg and neck US every few years.
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Introduction
The goal of monitoring patients with differentiated thyroid cancer (DTC), following total/
near total thyroidectomy and radioiodine treatment, is the early detection and treatment of 
persistent or recurrent disease. Although each of the staging systems extant may reliably 
predict disease-specific survival, they are less accurate at predicting disease recurrence, 
which can be observed in up to 30% of patients.1 Clinically evident disease recurrence has 
been described as many as 30–40 years after initial therapy, but large, retrospective studies 
consistently demonstrate that the vast majority of recurrences are detected in the first 10–15 
years of follow-up.2 Recent data from the National Thyroid Cancer Registry indicate that 
more than half of the recurrences occurred within 3 years in patients with micro-papillary 
thyroid cancer (PTC).3
Earlier monitoring techniques were relatively insensitive and used neck palpation and 
baseline serum thyroglobulin levels that had relatively poor sensitivity. Although not yet 
proven, it is likely that the increased sensitivity of the follow-up testing paradigm that is now 
recommended will identify recurrent or persistent disease earlier than when prior techniques 
were employed, resulting in higher rates of detection of recurrence within the first 5 years of 
follow-up with earlier potentially successful therapeutic intervention.
Current guidelines and consensus statements recommend measurement of TSH-stimulated 
Tg combined with ultrasound of the neck 6–12 months after the initial therapy.4–7 At this 
time, most patients (approximately 80%) will appear free of disease based on negative neck 
US and undetectable basal and stimulated serum Tg levels [with negative serum 
antithyroglobulin antibody (Tg Ab)]. Uncertainty persists regarding whether the subsequent 
follow-up should be based on the periodic measurement of basal serum Tg with neck US or 
whether rhTSH-stimulated Tg should be performed and at what frequency.4,8–12 Recently 
modified ATA guidelines recommend that low-risk patients who have had remnant ablation, 
negative US and undetectable rhTSH-stimulated Tg levels can be followed with yearly 
clinical examination and Tg measurements on levothyroxine replacement.4 This is a grade B 
recommendation based on studies that were limited by their number or consistency. There 
are no clear recommendations regarding the follow-up strategy in patients with moderate- to 
high-risk thyroid cancer who have no evidence of disease 1 year after the initial treatment.4
The goal of our study was to evaluate the utility of repeated rhTSH-stimulated Tg 
measurements in patients with DTC who have had no evidence of disease at an initial rhTSH 
stimulation test performed approximately 1 year after thyroidectomy and 131-I therapy.
Material and methods
The study was a retrospective analysis of medical records of patients with DTC treated 
and/or monitored at Washington Hospital Center, Washington, DC between years 1996 and 
2009.
Inclusion criteria: (i) DTC diagnosed after total or near total thyroidectomy; (ii) postsurgical 
treatment with one dose of 131-I; (iii) undetectable basal and rhTSH-stimulated serum Tg 
levels approximately 12 months after initial treatment; (iv) standard monitoring procedures 
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for at least 3 years. Patients with detectable anti-Tg antibodies at any time were excluded. 
The protocol was approved by the Institutional Review Board. Patient’s charts with ICD-9 
disease code 193 (thyroid cancer) followed at Washington Hospital Center between years 
1996 and 2009 were carefully reviewed to assess eligibility, and 278 individuals fulfilled the 
inclusion criteria and were analysed in the present study.
All patients underwent standard rhTSH stimulation testing.7 After drawing a baseline blood 
sample for Tg measurement, 0·9 mg rhTSH (Thyrogen®; Genzyme Corporation, Cambridge, 
MA, USA) was administered intramuscularly with a second injection repeated 24 h later. 
Blood specimens were obtained approximately 72 h after the second rhTSH dose. During 
the subsequent years of the follow-up period, Tg measurements were performed with four 
immunometric assays with functional sensitivities of 0·1, 0·2, 0·5 and 0·9 ng/ml and were 
analysed by Quest Diagnostics (Madison, NJ, USA), LabCorp (Burlington, NC, USA) and 
the Washington Hospital Center Laboratory (Washington, DC, USA). All patients were 
screened for anti-Tg antibody using the chemiluminescence immunoassay by the above-
mentioned laboratories. The sensitivity, specificity, negative predictive value (NPV) and 
positive predictive value (PPV) of stimulated Tg levels were assessed.
Results
The mean age at diagnosis, range of ages, gender breakdown, histologic type of cancer, 
clinical stage of disease, average activity of administered 131-I, range of 131-I dosages used 
in the treatment and the duration of follow-up are presented in Table 1.
All patients (278/278) had at least two rhTSH stimulation tests. The first test was performed 
approximately 1 year after initial treatment, serving as a parameter for the selection of 
patients eligible for the study (only patients with undetectable stimulated Tg levels were 
included), and the second test was performed 1–3 years after the first. In a large proportion 
of patients, additional rhTSH stimulation tests were performed. The total number of rhTSH 
stimulation tests performed during the follow-up period (3–12 years, mean 6·3) varied from 
two to seven (Fig. 1). During the interval of follow-up, cytological or biochemical evidence 
of potential persistent/recurrent disease was observed in 11/278 (4%) of patients (Table 2). 
There were no significant differences regarding stimulated TSH levels on day 5 after rhTSH 
in patients with biochemical or cytological evidence of potential persistent/recurrent disease, 
compared to the patients with no evidence of disease (mean TSH 9·1 uIU/ml vs TSH 11·2 
uIU/ml, respectively).
After having a negative initial Tg response to rhTSH, 10/278 patients (3·6%) had detectable 
rhTSH-stimulated Tg values: 9/10 after a second rhTSH stimulation and 1/10 after a third 
test (Table 2). Of these 10 patients, five had a stimulated Tg between 0·5 and less then 1 
ng/ml with no other direct evidence of disease. The remaining five patients had a rhTSH-
stimulated Tg level between 1 and 3·9 ng/ml. These five patients presented with suspicious 
cervical lymph nodes documented by neck US in four cases and cervical and mediastinal 
node enlargement documented by MRI in one case, and the latter patient subsequently 
presented with liver metastases (Table 2). Two of the five patients had had fine needle 
aspiration cytology (FNAC) confirmed disease. In one patient, the FNA was read as benign 
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but did not include assessment of Tg washouts. FNA was not performed in 2/5 – in one case 
because of the clinical decision of the attending physician and in one case because of the 
patient’s noncompliance.
Subsequent follow-up data enabled interpretation of the results of the second rhTSH 
stimulation test. In five cases (#6,7,8,9,10, Table 1), there was no evidence of disease during 
the whole follow-up period; in three cases, there was biochemical and/or cytological 
evidence of stable disease (patient #1,3,4, Table 1); in one case, there was an evidence of 
disease progression (patient #5, Table 1) and in one case, the results were inconclusive 
(patient #2, Table 1).
Only in two patients did unstimulated Tg rise to detectable values as measured by the assay 
with functional sensitivity of 0·2 ng/ ml – in patient #3, 7 years after the first biochemical 
evidence of disease provided by the rhTSH stimulation test and in patient #5 –4 years after 
the first evidence of disease recurrence based on detectable second stim-Tg level. There was 
no patient with undetectable rhTSH-stim Tg values, who presented with detectable baseline 
Tg levels. The disease course in patients with a positive second or third rhTSH stimulation 
test and the interpretation of biochemical and structural findings are summarized in Figs 2 
and 3.
Based on clinical decisions made by the attending endocrinologist, 9/11 patients were 
followed without further treatment. One patient (#4) underwent right neck dissection, 
documenting PTC in two cervical lymph nodes. Patient #5 who presented with the evidence 
of disease progression with biopsy proven metastases of PTC to the liver underwent 
cryoablation of the lesions.
In addition to the ten above-mentioned patients, one additional patient with undetectable first 
and second rhTSH-stimulated Tg values (<0·5 ng/ml) had FNAC proven residual disease in 
a cervical lymph node, detected 13 months after the initial treatment, and we consider this to 
reflect a false-negative rhTSH-Tg value (Patient 11, Table 2). The diagnostic accuracy of 
subsequent rhTSH-stimulated Tg tests performed after an initial negative one had been 
assessed in two contexts:
1. Does it change the therapeutic approach?
2. Does it change the management strategy?
In regard to the first question, only one patient presented with progressive disease warranting 
additional treatment. When a true-positive value is defined as associated with evidence of 
disease progression, the NPV of the first rhTSH-stimulated Tg is 99·6% and increases to 
100% with a second rhTSH-Tg stimulation with sensitivity 100%, specificity of 97·1%, but 
PPV of only 11·1%. In regard to the second question, a second rhTSH stimulation was of 
value for the one above-mentioned patient with evidence of progressive disease, but also for 
the patients with stable disease or inconclusive results of stimulated Tg. The NPV of the first 
rhTSH stimulation test in such circumstances is 97·8%, and when combined with neck US, it 
increases to 98%. Sensitivity, specificity, NPV and PPV of subsequent stimulations are 
summarized in Table 3. The combination of a second rhTSH-Tg stimulation test and a 
negative neck US results in NPV of 100% with sensitivity of 100%.
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Discussion
The results of the present study confirm the utility of a single rhTSH-Tg stimulation test 
performed 1 year after initial thyroidectomy and 131-I therapy. Subsequent rhTSH-Tg 
stimulation testing is of limited value as a tool indicating necessity for altered management 
or therapeutic intervention. A NPV of 99·6% for the first rhTSH-Tg stimulation test is a very 
good predictor of progression-free survival. Nevertheless, the second rhTSH stimulation test 
can be helpful in guiding the aggressiveness of the follow-up strategy. The NPV for disease-
free survival of the first rhTSH-Tg stimulation combined with a negative neck US is 98% 
and increases with a second stimulation test to 100% with sensitivity of 100%.
In a study of 68 patients, Castagna et al.9 suggested that repeated rhTSH stimulation testing 
was of limited value in patients with an initial negative test performed approximately 12 
months after initial therapy. In comparison with the latter report, the present study is based 
on larger number of patients (n = 278), inclusion of patients with more aggressive subtypes 
of thyroid cancer (columnar and tall cell variant of PTC, follicular thyroid cancer with 
poorly differentiated areas, Hurthle cell thyroid cancer), representation of all clinical stages 
of disease (clinical stage I–IV compared to I–III), longer duration of follow-up (mean 6·3 
years compared to 4·7 years) and a larger number of rhTSH stimulation tests (up to 7 
compared to 2).
Kloos and Mazzaferri reported a NPV of 98% for an undetectable first rhTSH-stimulated 
Tg, but the mean time for the first rhTSH stimulation test after initial therapy in their study 
was 5·5 years, which likely increased the NPV for being free of disease. Moreover, in their 
study, only 47% (32/68) of patients with an initial undetectable rhTSH-stimulated Tg level 
had undergone a second rhTSH stimulation over a mean 3·2-year follow-up period, which 
could have limited the identification of patients with persistent/recurrent disease.13
A lesson from our study is that although the majority of patients with detectable second or 
third stimulated Tg levels had negative or nonspecific imaging findings (neck US, WBS, CT, 
MRI or PET) and did not require further treatment, continued close monitoring of this group 
of patients was warranted. In patients with a history of DTC, the significance of detectable 
but small lymph nodes and persistent low levels of Tg without evidence of structural disease 
remains unknown,4 and the proper management of these patients can be a challenge. Some 
studies have suggested employing a cutoff value for a rhTSH-stimulated Tg level of >2 
ng/ml as indicating the need to consider additional evaluation and treatment during follow-
up.14 However, in a higher risk group of patients, Tg levels even below 2 ng/ml may suggest 
significant metastatic disease, as documented by Robbins et al.6 This was confirmed in our 
series, in which one patient with documented progressive disease had a relatively low 
rhTSH-stimulated Tg level of 1·5 ng/ml.
Recommendation 77 of the recently modified guidelines for thyroid cancer by the American 
Thyroid Association (ATA) indicates that in the absence of structurally evident disease, 
patients with rhTSH-stimulated Tg levels <5 ng/ml can be followed on treatment with 
levothyroxine only, reserving additional therapy for those patients with rising serum Tg 
levels or other evidence of disease progression during the follow-up period.4 Management 
Klubo-Gwiezdzinska et al. Page 5
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2018 August 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
questions facing the clinician include the frequency of repeat neck US, usefulness and 
frequency of performing subsequent rhTSH stimulations test, selection of patients likely to 
develop disease progression, the significance of metastatic disease in small lymph nodes and 
the risks of metastasis to distant sites during follow-up observation.
Taking into consideration that the optimal follow-up strategy should be based on tests with a 
high sensitivity for early detection of recurrent disease and a high NPV for disease 
recurrence, we suggest that a first rhTSH stimulation test combined with the neck US with 
NPV of 98% fulfils these requirements, but the second negative rhTSH-stimulated Tg test 
together with the negative neck US characterized by NPV of 100% and sensitivity of 100% 
can be further reassuring.
We propose that after having a negative second stimulation test, patients can be followed less 
aggressively. An optimal management strategy in this group of patients may be the 
measurement of baseline serum Tg measurements during levothyroxine treatment and neck 
US every few years. This is based on our observation that none of the patients with 
undetectable second rhTSH stimulation had any evidence of disease during the subsequent 
follow-up period. Our study also indicates that assessment of risk stratification should be 
dynamic and the intensity and methods of follow-up should be adjusted to new risk 
estimates that may evolve with time. Notably in our series, the proportion of patients 
categorized initially as high risk based on clinical staging was 11·9% for stage III, 1·8% for 
stage IVa and 0·4% for stage IVc. Moreover, patients with worrisome histology like 
columnar or tall cell variant PTC, Hurthle cell or follicular thyroid cancer with poorly 
differentiated areas, which formed 11·8% of the study population, had no evidence of 
disease during the follow-up period. Although the proportion of high-risk patients in our 
series was relatively small, it reflects what is commonly seen in clinical practice among 
patients who obtained complete remission after the initial treatment. The single patient with 
stage IVc disease in our series, who obtained transient remission after the initial treatment, 
but subsequently developed disease progression, was at continued high risk of mortality and 
morbidity of thyroid cancer. A limitation of the present study is its retrospective design 
which predicated use of Tg results from different clinical laboratories. On the other hand, 
our study reflects common clinical practice where Tg measurements occur in various 
laboratories over time. The functional sensitivity of the Tg assays used in our study varied 
from 0·1 to 0·9 ng/ml. Nevertheless, Schlumberger et al. have documented that disease 
detection by stimulated Tg measurements was similar for the Tg assays with functional 
sensitivity of 0·9 ng/ml compared to tests with functional sensitivity of 0·2–0·3 ng/ml. An 
advantage of the more sensitive assay, improved disease detection, was seen only with 
measurements during treatment with levothyroxine. A further decrease of functional 
sensitivity to 0·11 and 0·02 ng/ml increased the test sensitivity at the expense of decreased 
specificity.15 The strengths of our study include the analysis of a large number of patients, 
during a mean follow-up period exceeding 6 years (range up to 12 years), and inclusion of 
high-risk patients characterized by clinical stage III and IV disease or worrisome histology, 
with conclusions based on a large number of repeated rhTSH stimulation tests.
We conclude and recommend that in patients with differentiated thyroid cancer (i) the 
frequency and intensity of follow-up should be adjusted to new risk estimates evolving with 
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time; (ii) a first rhTSH-stimulated Tg at 1 year after initial treatment is an excellent predictor 
for remission and long-term disease-free survival independent of clinical stage at 
presentation and (iii) one additional negative rhTSH-Tg stimulation test at 3 years together 
with a negative neck ultrasonography will provide a negative predictive value of 100% and 
sensitivity of 100% and may be used as a tool selecting the patients who might be followed 
with baseline Tg measurement and neck ultrasonography every few years.
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Fig. 1. 
The number of repeated rhTSH stimulation tests during the follow-up period.
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Fig. 2. 
False-positive rhTSH stimulated Tg.
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Fig. 3. 
Follow-up data in patients with detectable stimulated Tg and abnormal imaging studies.
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Table 1
Demographics of patient population
Total number of patients 278
Mean age at diagnosis (years) 45·5 (±12·4)
Range of ages (years) 14–71
Female 226 (81·3%)
Male 52 (18·7%)
Histology
 Papillary thyroid cancer (PTC) 156/278 (56·1%)
 Follicular variant of PTC (PTCFV) 52/278 (18·7%)
 PTC columnar or tall cell variant 10/278 (3·6%)
 Follicular thyroid cancer (FTC) 24/278 (8·6%)
 FTC with poorly differentiated areas 2/278 (0·7%)
 Hurthle cell thyroid cancer 21/278 (7·5%)
 WDTC no detailed histological data* 13/278 (4·8%)
Clinical stage at presentation
 I 181/278 (65·1%)
 II 39/278 (14%)
 III 33/278 (11·9%)
 IVa 5/278 (1·8%)
 IVb 0/278 (0%)
 IVc 1/278 (0·4%)
 Unknown 19/278 (6·8%)
131-I dosage (mCi) (Mean ± SD) 136·8 (±29·5)
Range of 131-I dosage (mCi) 29–218
Duration of follow-up (years) (Mean ± SD) 6·3 (±2·5)
Range of follow-up period (years) 3–12
*WDTC documented in medical records, but no pathology report available.
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2018 August 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Klubo-Gwiezdzinska et al. Page 13
Ta
bl
e 
2
Th
e 
cl
in
ic
al
 c
ha
ra
ct
er
ist
ic
s o
f 1
1 
pa
tie
nt
s w
ith
 e
ith
er
 b
io
ch
em
ic
al
 o
r c
yt
ol
og
ic
al
 ev
id
en
ce
 o
f p
ot
en
tia
l r
es
id
ua
l t
hy
ro
id
 c
an
ce
r (
R,
 ri
gh
t, L
, le
ft)
Pa
tie
nt
 1
Pa
tie
nt
 2
Pa
tie
nt
 3
Pa
tie
nt
 4
Pa
tie
nt
 5
Pa
tie
nt
 6
Pa
tie
nt
 7
Pa
tie
nt
 8
Pa
tie
nt
 9
Pa
tie
nt
 1
0
Pa
tie
nt
 1
1
A
ge
 a
t d
ia
gn
os
is
32
39
23
33
62
56
69
25
36
64
26
Se
x
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
Fe
m
al
e
M
al
e
Fe
m
al
e
Pa
th
ol
og
y
PT
C
PT
C
FT
C
PT
C
PT
CF
V
PT
C 
ta
ll 
ce
ll 
v
ar
ia
nt
PT
C
PT
C
PT
C 
co
lu
m
na
r 
ce
ll 
va
ria
nt
PT
C
PT
C
St
ag
e
I
I
I
I
IV
c
IV
a
I
I
I
I
I
Tu
m
o
u
r 
siz
e 
(cm
)
2
1·
5
3 
× 
2·
5 
× 
2
N
o 
da
ta
2 
fo
ci
 1
·5
 an
d 
0·
2
3 
× 
1·
8 
× 
1·
8 
ex
tr
a-
th
yr
oi
d 
ex
te
ns
io
n
M
ul
tif
oc
al
, 
al
l f
oc
i <
1 
cm
0·
9 
m
in
 
ex
tr
a-
 
th
yr
oi
d 
ex
te
ns
io
n
2 
fo
ci
 0
·9
 
an
d 
0·
8
1·
2
1·
8 
× 
1·
3 
cm
 m
in
. 
ex
tr
a-
 
th
yr
oi
d 
ex
te
ns
io
n
Ly
m
ph
 n
od
e 
m
et
s 
at
 d
ia
gn
os
is
N
ot
 e
x
am
in
ed
Ye
s
N
ot
 e
x
am
in
ed
N
ot
 e
x
am
in
ed
Pr
es
en
t, 
an
d 
di
sta
nt
 m
et
 to
 
th
e 
oe
so
ph
ag
us
N
o
N
o
Ye
s
Ye
s
N
o
Ye
s
13
1-
I a
ct
iv
ity
 (m
Ci
)
15
0
13
0
15
0
N
o 
da
ta
15
0
15
0
10
3·
1
29
·4
15
7·
2
99
·5
15
0
St
im
 T
g1
 (n
g/m
l)
<
0·
5
<
0·
9
<
0·
2
<
0·
5
<
0·
9
<
0·
5
<
0·
5
<
0·
9
<
0·
5
<
0·
5
<
0·
5
St
im
 T
g2
 (n
g/m
l)
1·
0
3·
9
1·
0
2·
5
1·
5
0·
6
<
0·
5
0·
5
0·
6
0·
8
<
0·
5
St
im
 T
g3
 (n
g/m
l)
0·
6
<
0·
5
0·
6
Su
pp
re
ss
ed
 1
·2
0·
7
<
0·
2
<
0·
5
St
im
 T
g 
4 
(ng
/m
l)
1·
2
Su
pp
re
ss
ed
 4
<
0·
2
St
im
 T
g5
 (n
g/m
l)
1·
4
Su
pp
re
ss
ed
 7
·6
 
→
 97
·4
<
0·
2
D
ur
at
io
n 
of
 fo
llo
w
-
u
p 
(ye
ars
)
5
9
9 
(6·
 20
10
 
su
pp
re
ss
ed
 T
g 
0·
6)
6
7
6
7
7
8
7
3
Cl
in
ic
al
 fo
llo
w
-u
p
N
ec
k 
U
S:
 
st
ab
le
 1
·9
 ·×
 
0·
9 
× 
0·
4 
cm
 
R
 le
v
el
 II
I 
ce
rv
ic
al
 
ly
m
ph
 n
od
e 
w
ith
 
ca
lc
ifi
ca
tio
ns
, 
FN
A
 b
en
ig
n,
 
st
ab
le
 o
v
er
 
tim
e 
un
til
 
Ju
ly
 2
01
0
N
ec
k 
U
S:
 
L 
le
v
el
 II
I 
ly
m
ph
 
n
o
de
 2
·4
 ×
 
0·
3 
× 
0·
7,
 
st
ab
le
, 
FN
A
 n
ot
 
pe
rfo
rm
ed
, 
CT
 c
he
st,
 
ab
do
m
en
, 
pe
lv
is 
ne
g,
 
PE
T-
CT
 
n
eg
12
3-
I u
pt
ak
e:
 
an
te
rio
r l
ow
er
 
ce
rv
ic
al
 
re
gi
on
, n
ec
k 
U
S 
R 
ly
m
ph
 
n
o
de
 1
·3
 ×
 0
·3
 
×
 0
·8
 in
cr
ea
se
 
in
 si
ze
 1
·1
 ×
 
2·
2 
× 
0·
3 
cm
, 
FN
A
 (i
) 
n
o
n
di
ag
no
sti
c,
 
(ii
) n
ot 
pe
rfo
rm
ed
, 
ch
es
t C
T 
n
eg
at
iv
e
N
ec
k 
U
S:
 R
 
le
v
el
 II
I 
ly
m
ph
 n
od
es
 
1·
5 
× 
0·
3 
× 
0·
7 
cm
 a
nd
 
0·
6 
× 
0·
2 
× 
0·
6 
cm
., 
st
ab
le
 L
 tw
o
 
le
v
el
 II
 ly
m
ph
 
n
o
de
s 0
·7
 ×
 
0·
3 
× 
0·
8 
cm
 
an
d 
0·
9 
× 
0·
4 
×
 0
·7
 c
m
, 
st
ab
le
 Ju
ly
 
20
10
 R
 n
ec
k 
di
ss
ec
tio
n 
2 
Le
v
el
 IV
 L
 
ly
m
ph
 n
od
e 
1·
1 
× 
0·
6 
× 
1·
2 
FN
A
 –
 
n
eg
at
iv
e 
n
ec
k 
M
R
I s
ta
bl
e 
sli
gh
tly
 
en
la
rg
ed
 
ly
m
ph
 n
od
e 
at
 
th
e 
le
v
el
 o
f t
he
 
th
or
ac
ic
 in
le
t, 
PE
T-
CT
 n
eg
, 
PE
T-
CT
 3
 
m
o
n
th
s l
at
er
: 
R
 h
ep
at
ic
 lo
be
 
hy
po
de
ns
ity
,
 
N
ec
k 
U
S 
ne
g
12
3-
I 
u
pt
ak
e 
su
pr
as
te
rn
al
 
n
o
tc
h,
 n
ec
k 
M
R
I s
m
al
l 
be
ni
gn
 
ap
pe
ar
in
g 
ce
rv
ic
al
 
ly
m
ph
 
n
o
de
s, 
ch
es
t C
T 
n
eg
N
ec
k 
U
S 
ne
g
N
ec
k 
U
S 
ne
g
N
ec
k 
U
S 
ne
g
N
ec
k 
U
S 
re
sid
ua
l 
tis
su
e 
th
yr
oi
d 
be
d 
FN
A
C 
PT
C
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2018 August 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Klubo-Gwiezdzinska et al. Page 14
Pa
tie
nt
 1
Pa
tie
nt
 2
Pa
tie
nt
 3
Pa
tie
nt
 4
Pa
tie
nt
 5
Pa
tie
nt
 6
Pa
tie
nt
 7
Pa
tie
nt
 8
Pa
tie
nt
 9
Pa
tie
nt
 1
0
Pa
tie
nt
 1
1
LN
 p
os
iti
v
e 
PT
C
co
n
sp
ic
uo
us
 
by
 C
T,
 
bu
t 
w
ith
 n
o 
m
et
ab
ol
ic
 
ac
tiv
ity
 b
y 
PE
T 
sc
an
, 
M
R
I t
hr
ee
 
he
pa
tic
 le
sio
ns
 
2·
1,
 2
·6
 an
d 
1·
5c
m
 b
io
ps
y 
– 
tw
o
 le
sio
ns
 
po
sit
iv
e 
fo
r 
PT
C
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2018 August 09.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Klubo-Gwiezdzinska et al. Page 15
Ta
bl
e 
3
N
eg
at
iv
e 
(N
PV
) a
nd
 po
sit
ive
 (P
PV
) p
red
ict
ive
 v
al
ue
s, 
se
ns
iti
v
ity
 a
nd
 sp
ec
ifi
ci
ty
 o
f s
ub
se
qu
en
t s
tim
ul
at
ed
 T
g 
le
v
el
s
TP
FP
TN
FN
N
PV
 (%
)
PP
V
 (%
)
Se
ns
iti
v
ity
 (%
)
Sp
ec
ifi
ci
ty
 (%
)
Tg
1
0
0
27
2
6
97
·8
N
A
N
A
10
0
Tg
2
5
4
26
8
1
99
·6
55
·5
83
·3
98
·5
Tg
3
2
1
75
0
10
0
66
·6
10
0
98
·7
Tg
4
1
0
50
0
10
0
10
0
10
0
10
0
Tg
5
1
0
16
0
10
0
10
0
10
0
10
0
Tg
6
0
0
6
0
10
0
N
A
N
A
10
0
Tg
7
0
0
5
0
10
0
N
A
N
A
10
0
TP
,
 
tr
ue
-p
os
iti
v
e 
re
su
lt 
de
fin
ed
 a
s e
v
id
en
ce
 o
f d
ise
as
e 
pr
og
re
ss
io
n 
(in
cre
asi
ng
 T
g l
ev
el
 a
nd
/o
r i
nc
re
as
in
g 
siz
e 
of
 m
et
as
ta
tic
 fo
ci
), s
tab
le 
dis
ea
se 
(st
ab
le 
de
tec
tab
le 
Tg
 an
d s
tab
le 
im
ag
ing
 st
ud
ies
) o
r 
in
co
nc
lu
siv
e 
re
su
lts
 o
f r
hT
SH
-T
g 
sti
m
ul
at
io
n 
te
sts
 d
ur
in
g 
fo
llo
w
-u
p 
pe
rio
d.
FP
,
 
fa
lse
-p
os
iti
v
e 
re
su
lt 
de
fin
ed
 a
s d
et
ec
ta
bl
e 
rh
TS
H
-T
g 
an
d 
no
 o
th
er
 ev
id
en
ce
 o
f d
ise
as
e 
du
rin
g 
th
e 
fo
llo
w
-u
p 
pe
rio
d.
TN
, t
ru
e-
ne
ga
tiv
e 
re
su
lt 
de
fin
ed
 a
s u
nd
et
ec
ta
bl
e 
Tg
 a
nd
 n
o 
ev
id
en
ce
 o
f d
ise
as
e 
du
rin
g 
fo
llo
w
-u
p 
pe
rio
d 
(bi
oc
he
mi
ca
l a
nd
 cy
to
lo
gi
ca
l a
nd
 b
as
ed
 o
n 
ab
no
rm
al
 im
ag
in
g 
stu
di
es
).
FN
, f
al
se
 n
eg
at
iv
e 
de
fin
ed
 a
s u
nd
et
ec
ta
bl
e 
Tg
 a
nd
 ev
id
en
ce
 o
f d
ise
as
e 
(bi
oc
he
mi
ca
l a
nd
/or
 cy
to
lo
gi
ca
l a
nd
/o
r b
as
ed
 o
n 
ab
no
rm
al
 im
ag
in
g 
stu
di
es
).
Clin Endocrinol (Oxf). Author manuscript; available in PMC 2018 August 09.
